A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2019
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jan 2019 Study design has been changed from Parallel Assignment to Single Group Assignment and number of treatment arms decreased.
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2017 Status changed from not yet recruiting to recruiting.